Identification of m6A/m5C-related lncRNA signature for prediction of prognosis and immunotherapy efficacy in esophageal squamous cell carcinoma

N6-methyladenosine (m6A) and 5-methylcytosine (m5C) RNA modifications have garnered significant attention in the field of epigenetic research due to their close association with human cancers. This study we focus on elucidating the expression patterns of m6A/m5C-related long non-coding RNAs (lncRNAs...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2024-04, Vol.14 (1), p.8238-8238, Article 8238
Main Authors: Wang, Jianlin, Ren, Huiwen, Xu, Chao, Yu, Bo, Cai, Yiling, Wang, Jian, Ni, Xinye
Format: Article
Language:English
Subjects:
631/61/191
631/61/212
631/61/54
Adenine
CD4 antigen
Epigenetics
Esophageal cancer
Esophageal carcinoma
Esophageal Neoplasms - genetics
Esophageal Neoplasms - therapy
Esophageal squamous cell carcinoma
Esophageal Squamous Cell Carcinoma - genetics
Esophageal Squamous Cell Carcinoma - therapy
Humanities and Social Sciences
Humans
Immune checkpoint inhibitors
Immunological memory
Immunotherapy
lncRNA
Lymphocytes T
m5C
m6A
Medical prognosis
Memory cells
Microenvironments
multidisciplinary
N6-methyladenosine
Non-coding RNA
Patients
Predictions
Prognosis
RNA, Long Noncoding - genetics
Science
Science (multidisciplinary)
Squamous cell carcinoma
Survival
Transcriptomics
Tumor Microenvironment - genetics
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:N6-methyladenosine (m6A) and 5-methylcytosine (m5C) RNA modifications have garnered significant attention in the field of epigenetic research due to their close association with human cancers. This study we focus on elucidating the expression patterns of m6A/m5C-related long non-coding RNAs (lncRNAs) in esophageal squamous cell carcinoma (ESCC) and assessing their prognostic significance and therapeutic potential. Transcriptomic profiles of ESCC were derived from public resources. m6A/m5C-related lncRNAs were obtained from TCGA using Spearman’s correlations analysis. The m6A/m5C-lncRNAs prognostic signature was selected to construct a RiskScore model for survival prediction, and their correlation with the immune microenvironment and immunotherapy response was analyzed. A total of 606 m6A/m5C-lncRNAs were screened, and ESCC cases in the TCGA cohort were stratified into three clusters, which showed significantly distinct in various clinical features and immune landscapes. A RiskScore model comprising ten m6A/m5C-lncRNAs prognostic signature were constructed and displayed good independent prediction ability in validation datasets. Patients in the low-RiskScore group had a better prognosis, a higher abundance of immune cells (CD4 + T cell, CD4 + naive T cell, class-switched memory B cell, and Treg), and enhanced expression of most immune checkpoint genes. Importantly, patients with low-RiskScore were more cline benefit from immune checkpoint inhibitor treatment ( P  
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-024-58743-y